The Journal of Organic Chemistry
Article
1
35%) as an orange solid: H NMR (300 MHz, CDCl3): δ 3.62−3.65
151.8 (C), 152.3 (CO), 162.3 (C), 162.7 (C); HRMS (m/z): [M +
H+] calcd for C26H18ClN2O3, 441.1000; found, 441.1010.
(m, 2H), 3.66−3.75 (m, 11H), 7.23 (br s, 1H), 7.73 (d, J = 8.8 Hz,
2H), 8.15 (d, J = 8.7 Hz, 2H); 13C NMR (75.5 MHz, CDCl3): δ 40.2
(CH2), 61.8 (CH2), 69.9 (CH2), 70.4 (CH2), 70.5 (CH2), 72.6 (CH2),
124.7 (2 × CH), 129.3 (2 × CH), 135.0 (C), 138.8 (C), 161.9 (C−
O−), 165.4 (CO), missing C−Cl signal due to relaxation issue;
HRMS (m/z): [M+Na+] calcd for C15H18ClN3O6Na, 394.0776; found,
394.0775.
General Procedure for the Cycloaddition of Fl-DIBO with
Various Sydnones. A solution of Fl-DIBO (3) (14.4 mg, 0.05 mmol)
and the respective sydnone (0.1 mmol) in a mixture of dichloro-
methane and methanol (4:1, 5 mL, solvent system A) or a mixture of
1,2-dichloroethane and methanol (4:1, 5 mL, solvent system B) was
stirred at 50 °C (system A) or 70 °C (system B). All volatiles were
then removed under reduced pressure, and the residue was purified by
flash chromatography on silica gel (5 g) using a mixture of 1% of
methanol in dichloromethane, affording the desired pure cycloadducts,
respectively.
3-Bromo-5,11-dimethoxy-2-phenyldibenzo[3,4:7,8]cyclopropa-
[5,6]cycloocta[1,2-c]pyrazol-8(2H)-one 6f. Obtained with system A
overnight. Off-white solid (21 mg, 88%): 1H NMR (300 MHz,
CDCl3): δ 3.86 (s, 3H), 3.89 (s, 3H), 6.93 (dd, J = 8.5, 2.7 Hz, 1H),
6.95 (dd, J = 8.5, 2.7 Hz, 1H), 7.16 (d, J = 2.6 Hz, 1H), 7.31 (d, J = 2.6
Hz, 1H), 7.47−7.64 (m, 7H); 13C NMR (75.5 MHz, CDCl3): δ 55.7
(CH3), 55.8 (CH3), 113.5 (CH), 114.9 (CH), 116.8 (C−Br), 117.6
(CH), 118.0 (C), 119.2 (C), 119.9 (CH), 120.2 (C), 126.2 (2 × CH),
129.2 (2 × CH), 129.3 (CH), 132.8 (CH), 133.0 (CH), 135.3 (C),
138.1 (C), 139.0 (C), 149.3 (C), 151.4 (C), 152.1 (C), 152.2 (C
O), 162.2 (C), 162.6 (C); HRMS (m/z): [M + H+] calcd for
C26H18BrN2O3, 485.0495; found, 485.0494.
3-Iodo-5,11-dimethoxy-2-phenyldibenzo[3,4:7,8]cyclopropa[5,6]-
cycloocta[1,2-c]pyrazol-8(2H)-one 6g. Obtained with system A
during 24 h. Yellow solid (11 mg, 41%): 1H NMR (300 MHz,
CDCl3): δ 3.86 (s, 3H), 3.91 (s, 3H), 6.94 (dd, J = 8.5, 2.6 Hz, 1H),
6.95 (dd, J = 8.5, 2.7 Hz, 1H), 7.18 (d, J = 2.6 Hz, 1H), 7.30 (d, J = 2.6
Hz, 1H), 7.49−7.57 (m, 5H), 7.59 (d, J = 8.5 Hz, 1H), 7.61 (d, J = 8.5
Hz, 1H); 13C NMR (75.5 MHz, CDCl3): δ 55.7 (CH3), 55.8 (CH3),
91.1 (C−I), 113.7 (CH), 114.9 (CH), 117.5 (CH), 118.1 (C), 119.5
(C), 120.4 (CH), 125.5 (C), 127.0 (2 × CH), 129.2 (2 × CH), 129.5
(CH), 132.6 (CH), 133.0 (CH), 136.6 (C), 138.1 (C), 140.6 (C),
149.5 (C), 151.7 (C), 152.2 (C), 152.5 (CO), 162.0 (C), 162.6
(C); HRMS (m/z): [M + H+] calcd for C26H18IN2O3, 533.0357;
found, 533.0357.
5,11-Dimethoxy-2-phenyldibenzo[3,4:7,8]cyclopropa[5,6]-
cycloocta[1,2-c]pyrazol-8(2H)-one 6a. Obtained with system A
overnight. Light yellow solid (18 mg, 89%): H NMR (300 MHz,
1
CDCl3): δ 3.89 (s, 3H), 3.91 (s, 3H), 6.89 (dd, J = 8.5, 2.5 Hz, 1H),
6.95 (dd, J = 8.5, 2.7 Hz, 1H), 7.00 (d, J = 2.5 Hz, 1H), 7.34 (tt, J =
7.4, 1.5 Hz, 1H), 7.43 (d, J = 2.7 Hz, 1H), 7.48 (t, J = 7.4 Hz, 2H),
7.63 (d, J = 8.5 Hz, 1H), 7.65 (d, J = 8.5 Hz, 1H), 7.74 (dd, J = 7.4, 1.5
Hz, 2H), 7.86 (s, 1H); 13C NMR (75.5 MHz, CDCl3): δ 55.8 (2 ×
CH3), 112.6 (CH), 114.5 (CH), 117.4 (C), 117.7 (CH), 117.7 (C),
118.3 (CH), 119.1 (2 × CH), 122.3 (C), 127.4 (CH), 129.7 (2 ×
CH), 130.7 (CH), 133.7 (CH), 134.0 (CH), 137.0 (C), 138.3 (C),
139.3 (C), 148.4 (C), 149.8 (C), 150.2 (C), 152.8 (CO), 162.6
(C), 162.9 (C); HRMS (m/z): [M + H+] calcd for C26H19N2O3,
407.1390; found, 407.1393.
3-Chloro-5,11-dimethoxy-2-[4-(trifluoromethyl)phenyl]dibenzo-
[3,4:7,8]cyclopropa[5,6]cycloocta[1,2-c]pyrazol-8(2H)-one 6h. Ob-
1
tained with system A overnight. Off-white solid (25 mg, 98%): H
NMR (300 MHz, CDCl3): δ 3.88 (s, 3H), 3.90 (s, 3H), 6.95 (dd, J =
8.7, 2.6 Hz, 1H), 6.98 (dd, J = 8.7, 2.6 Hz, 1H), 7.13 (d, J = 2.6 Hz,
1H), 7.31 (d, J = 2.6 Hz, 1H), 7.62 (d, J = 8.6 Hz, 1H), 7.66 (d, J = 8.6
Hz, 1H), 7.80 (s, 4H); 13C NMR (75.5 MHz, CDCl3): δ 55.7 (CH3),
55.8 (CH3), 113.5 (CH), 114.9 (CH), 117.8 (CH), 117.9 (C−Cl),
118.3 (C), 119.1 (C), 119.5 (CH), 123.7 (q, J = 271.7 Hz, C), 125.5
(2 × CH), 126.5 (q, J = 3.6 Hz, 2 × CH), 128.2 (C), 131.0 (q, J = 33.2
Hz, C), 133.0 (CH), 133.2 (CH), 134.1 (C), 137.7 (C), 140.8 (C),
149.8 (C), 151.3 (C), 151.9 (C), 152.1 (CO), 162.4 (C), 162.6
(C); 19F NMR (282 MHz, CDCl3): δ − 62.62 (s); HRMS (m/z): [M
+ H+] calcd for C27H17ClF3N2O3, 509.0874; found, 509.0876.
5,11-Dimethoxy-2,3-diphephenyldibenzo[3,4:7,8]cyclopropa-
[5,6]cycloocta[1,2-c]pyrazol-8(2H)-one 6j. Obtained with system B
during 120 h. Yellow solid (10 mg, 42%): 1H NMR (300 MHz,
CDCl3): δ 3.30 (s, 3H), 3.93 (s, 3H), 6.29 (d, J = 2.6 Hz, 1H), 6.75
(dd, J = 8.5, 2.6 Hz, 1H), 6.81−7.06 (m, 3H), 7.16−7.35 (m, 8H),
7.50 (d, J = 2.6 Hz, 1H), 7.58 (d, J = 8.5 Hz, 1H), 7.62 (d, J = 8.5 Hz,
1H); 13C NMR (75.5 MHz, CDCl3): δ 55.2 (CH3), 55.7 (CH3), 114.4
(CH), 114.6 (CH), 117.9 (CH), 118.0 (C), 119.1 (CH), 119.4 (C),
125.3 (2 × CH), 127.9 (CH), 128.7 (CH), 128.8 (2 × CH), 129.0 (2
× CH), 130.0 (2 × C), 130.9 (2 × CH), 132.5 (CH), 133.3 (CH),
136.6 (C), 138.7 (C), 139.5 (C), 144.5 (C), 148.7 (C), 151.4 (C),
151.9 (C), 152.6 (CO), 161.8 (C), 162.6 (C); HRMS (m/z): [M +
H+] calcd for C32H23N2O3, 483.1703; found, 483.1710.
5,11-Dimethoxy-2-(4-methoxyphenyl)dibenzo[3,4:7,8]-
cyclopropa[5,6]cycloocta[1,2-c]pyrazol-8(2H)-one 6b. Obtained
with system B during 48 h. Light yellow solid (14 mg, 65%): H
1
NMR (300 MHz, CDCl3): δ 3.85 (s, 3H), 3.88 (s, 3H), 3.90 (s, 3H),
6.87 (dd, J = 8.5, 2.6 Hz, 1H), 6.93 (dd, J = 8.5, 2.7 Hz, 1H), 6.06−
6.99 (m, 3H), 7.41 (d, J = 2.7 Hz, 1H), 7.61 (d, J = 8.5 Hz, 1H), 7.62
(d, J = 8.5 Hz, 1H), 7.63 (d, J = 9.1 Hz, 2H), 7.76 (s, 1H); 13C NMR
(75.5 MHz, CDCl3): δ 55.7 (3 × CH3), 112.5 (CH), 114.3 (CH),
114.7 (2 × CH), 117.4 (C), 117.6 (CH), 117.7 (C), 118.2 (CH),
120.8 (2 × CH), 121.8 (C), 130.8 (CH), 133.0 (C), 133.7 (CH),
133.9 (CH), 137.1 (C), 138.4 (C), 147.8 (C), 149.9 (C), 150.2 (C),
152.8 (CO), 158.9 (C), 162.6 (C), 162.8 (C); HRMS (m/z): [M +
H+] calcd for C27H21N2O4, 437.1496; found, 437.1500.
5,11-Dimethoxy-2-(4-trimethylfluorophenyl)dibenzo[3,4:7,8]-
cyclopropa[5,6]-cycloocta[1,2-c]pyrazol-8(2H)-one 6c. Obained with
system A overnight. Light yellow solid (23 mg, 97%): H NMR (300
1
MHz, CDCl3): δ 3.89 (s, 3H), 3.91 (s, 3H), 6.90 (dd, J = 8.5, 2.6 Hz,
1H), 6.97 (dd, J = 8.5, 2.7 Hz, 1H), 7.01 (d, J = 2.6 Hz, 1H), 7.41 (d, J
= 2.7 Hz, 1H), 7.64 (d, J = 8.5 Hz, 1H), 7.65 (d, J = 8.5 Hz, 1H), 7.74
(d, J = 8.6 Hz, 2H), 7.87 (d, J = 8.6 Hz, 2H), 7.93 (s, 1H); 13C NMR
(75.5 MHz, CDCl3): δ 55.8 (CH3), 55.8 (CH3), 112.8 (CH), 114.5
(CH), 117.4 (C), 117.6 (C), 117.8 (CH), 118.4 (CH), 118.7 (2 ×
CH), 123.2 (C), 123.9 (q, J = 272.0 Hz, CF3), 127.0 (q, J = 3.7 Hz, 2
× CH), 129.2 (q, J = 33.0 Hz, C), 130.6 (CH), 133.8 (CH), 134.0
(CH), 136.5 (C), 137.8 (C), 141.6 (C), 149.4 (C), 149.7 (C), 150.1
(C), 152.7 (CO), 162.6 (C), 162.9 (C); 19F NMR (282 MHz,
CDCl3): δ − 62.35 (s); HRMS (m/z): [M + H+] calcd for
C27H18F3N2O3, 475.1264; found, 475.1269.
3-Chloro-5,11-dimethoxy-2-phenyldibenzo[3,4:7,8]cyclopropa-
[5,6]cycloocta[1,2-c]pyrazol-8(2H)-one 6e. Obtained with system A
overnight. Yellowish solid (21 mg, 93%): 1H NMR (300 MHz,
CDCl3): δ 3.87 (s, 3H), 3.89 (s, 3H), 6.94 (dd, J = 8.6, 2.5 Hz, 1H),
6.96 (dd, J = 8.5, 2.6 Hz, 1H), 7.14 (d, J = 2.6 Hz, 1H), 7.33 (dd, J =
2.5 Hz, 1H), 7.49−7.56 (m, 3H), 7.60−7.66 (m, 4H); 13C NMR (75.5
MHz, CDCl3): δ 55.8 (CH3), 55.8 (CH3), 113.4 (CH), 114.9 (CH),
117.3 (C−Cl), 117.7 (CH), 117.8 (C), 119.1 (C), 119.4 (CH), 125.6
(2 × CH), 128.3 (C), 129.2 (CH), 129.3 (2 × CH), 133.0 (CH),
133.2 (CH), 134.6 (C), 138.1 (C), 138.2 (C), 148.8 (C), 151.2 (C),
5,11-Dimethoxy-3-(methylsulfanyl)-2-phenyldibenzo[3,4:7,8]-
cyclopropa[5,6]-cycloocta[1,2-c]pyrazol-8(2H)-one 6k. Obtained
1
with system B during 48 h. Yellow solid (21 mg, 91%): H NMR
(300 MHz, CDCl3): δ 1.79 (s, 3H), 3.85 (s, 3H), 3.90 (s, 3H), 6.94
(dd, J = 8.5 Hz, 2.6 Hz, 1H), 6.93 (dd, J = 8.5 Hz, 2.6 Hz, 1H), 7.26
(d, J = 2.6 Hz, 1H), 7.32 (d, J = 2.6 Hz, 1H), 7.45−7.54 (m, 3H),
7.57−7.64 (m, 4H); 13C NMR (75.5 MHz, CDCl3): δ 18.6 (CH3),
55.7 (CH3), 55.8 (CH3), 113.6 (CH), 114.7 (CH), 117.6 (CH), 117.9
(C), 119.2 (C), 119.8 (CH), 123.6 (C), 126.0 (2 × CH), 128.9 (CH),
129.1 (2 × CH), 132.5 (CH), 132.9 (CH), 136.2 (C), 137.7 (C),
138.5 (C), 139.5 (C), 148.7 (C), 151.6 (C), 152.3 (C), 152.4 (C
O), 162.2 (C), 162.6 (C); HRMS (m/z): [M + H+] calcd for
C27H21N2O3S, 453.1267; found, 453.1265.
5,11-Dimethoxy-2-(4-isopropylamidophenyl)dibenzo[3,4:7,8]-
cyclopropa[5,6]-cycloocta[1,2-c]pyrazol-8(2H)-one 6l. Obtained
with system B overnight. yellow solid (4 mg, 16%, low yield due to
G
J. Org. Chem. XXXX, XXX, XXX−XXX